Total trials
66
Active
12
Phase 3
15
Total enrollment
10,706
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery | — | — | — | — | — | 1 | |
| Travoprost Intraocular Implant | — | — | — | — | — | 1 | |
| Riboflavin Ophthalmic Solutions | — | — | — | — | — | 1 | |
| Gen 2 Travoprost Intracameral Implant | — | — | — | — | — | 2 | |
| Timolol eye drops 0.5% | — | — | — | — | — | 2 | |
| Vehicle | — | — | — | — | — | 2 | |
| NXL Energy 1 | — | — | — | — | — | 1 | |
| NXL Energy 2 | — | — | — | — | — | 1 | |
| NXL Energy 3 | — | — | — | — | — | 1 | |
| Sham Treatment | — | — | — | — | — | 1 | |
| GLK-221 Ophthalmic Solution | — | — | — | — | — | 1 | |
| lufepirsen high dose | — | — | — | — | — | 1 | |
| lufepirsen low dose | — | — | — | — | — | 1 | |
| GLK-321 low dose BID | — | — | — | — | — | 1 | |
| GLK-321 mid dose BID | — | — | — | — | — | 1 | |
| GLK-321 high dose BID | — | — | — | — | — | 1 | |
| GLK-321 high dose QD | — | — | — | — | — | 1 | |
| Travoprost | — | — | — | 4 |
Next readouts
- 2025-08
- 2025-12
- 2026-06
- 2026-08
- 2026-09
- 2027-04
- 2027-05
- 2027-09
- 2028-03
- 2028-06
Top conditions
- Glaucoma, Open-Angle11
- Glaucoma9
- Keratoconus6
- Open-Angle Glaucoma6
- Open-angle Glaucoma6
- Ocular Hypertension5
- Open Angle Glaucoma4
- Progressive Keratoconus3
Frequently asked questions about Glaukos Corporation
- How many clinical trials does Glaukos Corporation have on ClinicalTrials.gov?
- Glaukos Corporation is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Glaukos Corporation's trials are in Phase 3?
- 15 of Glaukos Corporation's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Glaukos Corporation focus on?
- Glaukos Corporation's most-studied conditions on ClinicalTrials.gov are Glaucoma, Open-Angle, Glaucoma, Keratoconus, Open-Angle Glaucoma, Open-angle Glaucoma.
- When are Glaukos Corporation's next clinical trial readouts?
- Glaukos Corporation has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus”, expected around 2025-08.